Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
Navigating Therapeutic Challenges in BRAF-Mutated NSCLC: Non-V600 Mutations, Immunotherapy, and Overcoming Resistance.
Bortolot M et al.
International Journal of Molecular Sciences, 2024
Exploring immunotherapy efficacy in non-small cell lung cancer patients with BRAF mutations: a case series and literature review.
Chmielewska I et al.
Translational Lung Cancer Research, 2024
Outcomes of non-small cell lung cancer patients with non-V600E BRAF mutations: a series of case reports and literature review.
Lazar R et al.
Frontiers in Oncology, 2024
PD-L1-negative non-small cell lung cancer harbouring a rare BRAF mutation with successful treatment of first-line pembrolizumab plus chemotherapy: A case report and review the literature.
Do KH et al.
Respirology Case Reports, 2023
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
32958805 (PubMed )
Supplement: 41598_2020_72404_MOESM2_ESM.xlsx › ClinVar
Select a paper to view details